Community Update on the MDL-101 Program for LAMA2-Related Dystrophy

As the MDL-101 program continues to advance toward clinical development, interest and inquiries from the LAMA2-RD community have increased significantly. To ensure that all patients and families receive fair, transparent, and consistent information, Modalis Therapeutics, Cure CMD, and Voor Sara have jointly prepared the following update on the current status of the program.
We are grateful for the continued support and engagement of the community and remain committed to sharing additional information as it becomes available.

Please refer to the joint statement here.